Gyre Therapeutics (NASDAQ:GYRE) Rating Lowered to “Strong Sell” at Zacks Research

Gyre Therapeutics (NASDAQ:GYRE) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on GYRE. Wall Street Zen cut shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Gyre Therapeutics in a report on Friday, August 7th. Two investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Gyre Therapeutics has an average rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Stock Up 2.4%

Shares of Gyre Therapeutics stock opened at $7.15 on Tuesday. The firm has a market cap of $797.30 million, a P/E ratio of -34.05 and a beta of 1.92. The business has a 50-day moving average price of $6.38 and a 200 day moving average price of $7.00. Gyre Therapeutics has a fifty-two week low of $5.44 and a fifty-two week high of $9.42.

Gyre Therapeutics (NASDAQ:GYRE) last issued its earnings results on Friday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The business had revenue of $29.11 million for the quarter, compared to analyst estimates of $26.49 million. Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%. As a group, equities research analysts anticipate that Gyre Therapeutics will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On Gyre Therapeutics

Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE grew its stake in Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after acquiring an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Gyre Therapeutics by 84.6% in the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after purchasing an additional 3,244 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of Gyre Therapeutics during the fourth quarter worth approximately $77,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Gyre Therapeutics by 132.4% during the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after purchasing an additional 7,361 shares during the period. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.